AstraZeneca Acquires EsoBiotec to Advance In Vivo Cell Therapy

AstraZeneca has taken a major leap in the world of oncology and immunotherapy with its acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies. Unlike traditional cell therapies that require weeks of complex processing, EsoBiotec’s innovative ENaBL platform reprograms immune cells directly within the patient’s body, allowing for treatment through a simple IV injection. This cutting-edge approach could revolutionize cancer treatment, offering a faster and more accessible solution for patients worldwide. The acquisition strengthens AstraZeneca’s commitment to cell therapy innovation and accelerates the development of next-generation cancer treatments.

Jean-Pierre Latere, CEO of EsoBiotec, expressed enthusiasm for joining forces with AstraZeneca, highlighting the shared vision of delivering cost-effective and scalable therapies. Susan Galbraith, AstraZeneca’s EVP of Oncology R&D, emphasized that this partnership marks a significant step toward harnessing the full potential of cell therapy. With EsoBiotec now a wholly owned subsidiary operating in Belgium, AstraZeneca is poised to lead the charge in transforming the future of cancer care.